NCT01751074View on ClinicalTrials.gov

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 17, 2012

Primary Completion Date

March 14, 2013

Study Completion Date

March 14, 2013

Conditions
Atherosclerosis
Interventions
DRUG

Rosuvastatin 10 mg

Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).

DRUG

Darapladib 160 mg

Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).

Trial Locations (1)

91206

GSK Investigational Site, Glendale

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01751074 - To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers | Biotech Hunter | Biotech Hunter